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ABSTRACT
In response to genotoxic stress the TP53 tumour sup-
pressor activates target gene expression to induce
cell cycle arrest or apoptosis depending on the ex-
tent of DNA damage. These canonical activities can
be repressed by TP63 in normal stratifying epithelia
to maintain proliferative capacity or drive prolifera-
tion of squamous cell carcinomas, where TP63 is fre-
quently overexpressed/amplified. Here we use ChIP-
sequencing, integrated with microarray analysis, to
define the genome-wide interplay between TP53 and
TP63 in response to genotoxic stress in normal cells.
We reveal that TP53 and TP63 bind to overlapping,
but distinct cistromes of sites through utilization of
distinctive consensus motifs and that TP53 is consti-
tutively bound to a number of sites. We demonstrate
that cisplatin and adriamycin elicit distinct effects
on TP53 and TP63 binding events, through which
TP53 can induce or repress transcription of an ex-
tensive network of genes by direct binding and/or
modulation of TP63 activity. Collectively, this results
in a global TP53-dependent repression of cell cycle
progression, mitosis and DNA damage repair con-
comitant with activation of anti-proliferative and pro-
apoptotic canonical target genes. Further analyses
reveal that in the absence of genotoxic stress TP63
plays an important role in maintaining expression of
DNA repair genes, loss of which results in defective
repair.
INTRODUCTION
The TP53 family of transcription factors comprises three
ancestrally conserved members TP53, TP63 and TP73,
which play critical roles in development, growth control,
differentiation, cellular homeostasis and response to geno-
toxic and other types of stress (reviewed in (1,2)). While
many overlapping functions have been described for TP53
family members, knockout studies and germline mutations
reveal strikingly distinct phenotypes (3,4). Trp53 knock-
out mice and patients with germline TP53 mutations (Li-
Fraumeni syndrome––LFS) (4,5) are highly cancer prone,
whereas Trp63 deficiency is perinatally lethal (3,6) due to a
lack of skin and other developmental defects that are shared
by patients with a spectrum of syndromes associated with
TP63 mutations (7).
TP53 family members share highly conserved core DNA
binding and oligomerization domains, which facilitate
tetramerization and DNA binding to TP53 response ele-
ments consisting of two decamers ‘RRRCWWGYYY’ sep-
arated by spacers of variable length (8). Target specificity is
still poorly understood, but can be achieved through differ-
ential binding of family members and their respective iso-
forms to variable response elements to modulate transcrip-
tion through intra- and inter-molecular interactions and
post-translational modifications.
The transcriptional program regulated by TP53 repre-
sents a potent tumour suppressive pathway, which regulates
expression of a network of genes in response to a range of
stresses to induce cell cycle arrest, DNA repair, senescence
or apoptosis (9). As such, TP53 is seen as a critical barrier
to tumourigenesis and loss of wild-type p53 function oc-
curs in more than half of all tumours through either muta-
tion or compromised function caused by a variety of mech-
anisms including viral oncoproteins such as Human Papil-
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loma Virus E6 (10) or overexpression of negative regulators
such as MDM2 and PPM1D (11,12).
Expression of TP53 responsive genes can further be in-
fluenced by expression of the TP53 family members TP63
and TP73 and recent evidence suggests that all three family
members can in certain contexts act as tumour suppressors
or oncogenes dependent on the expression of other family
members and their isoforms (reviewed in (1)). This is likely
due to the transcriptional complexity exhibited by all three
family members, which encode multiple isoforms as a result
of alternative splicing and alternate promoter usage (2).
Unlike TP53 the role of TP63 in cancer is less clear.
It is mutated in ∼7% of squamous cell carcinomas (13)
and overexpressed/amplified in the majority of squamous
cell carcinomas. However, expression is lost in other ep-
ithelial cancers such as breast, prostate and bladder tu-
mours (14,15,16). Recent data suggests thatNTP63 rep-
resents a proto-oncogene, whereas TP63 behaves as a haplo-
insufficient tumour suppressor and that these latter func-
tions can be de-regulated by certain TP53 mutations (17–
19).
The pervading model for the functional interplay be-
tween TP53 and TP63 is based largely on a relatively small
number of canonical p53 activated anti-proliferative and
pro-apoptotic target genes. TheNTP63 isoform opposes
TP53- and TP73-mediated activation of anti-proliferative
and pro-apoptotic target to promote proliferation and
survival (20). For instance, in response to DNA dam-
age NTP63 can oppose TP53-mediated activation of
anti-proliferative and pro-apoptotic target genes including
CDKN1A, BAXandFAS (21). However, there is increasing
evidence to suggest that TP53 can play both direct and indi-
rect roles in the negative regulation of gene repression in re-
sponse to genotoxic stress (22). Furthermore, recent studies
in mice suggest that the transcriptional activation function
of TP53 is at least in part dispensable for its tumour suppres-
sive functions (23), underlining the importance of charac-
terizing the genome-wide interplay that exists between these
transcription factors.
The extent of this interplay is highlighted by recent stud-
ies fromour laboratory and others, identifying dual roles for
NTP63 in the regenerating epidermis opposing TP53 ac-
tivity to maintain proliferative capacity (24,25), whilst also
being required for TP53 independent growth and differen-
tiation (25). In addition, comparison of our recent TP63
ChIP-seq (26) analysis of genome-wide TP63 binding sites
in primary human keratinocytes with TP53 ChIP-seq from
disparate cell types (27–29) revealed more than 1000 over-
lapping binding sites.
Here we report the first genome-wide analysis of TP53
and TP63 binding sites in human keratinocytes. Using in-
tegrative analyses, we reveal that in response to genotoxic
stress, changes in TP53 and TP63 bound cistromes result in
induction or repression of a large network of target genes,
the dynamics of which depends on the nature of the geno-
toxic stress.
Collectively, through direct effects of TP53 binding or
indirect inactivation of TP63 this results in global repres-
sion of cell cycle and DNA damage repair genes concomi-
tant with activation of anti-proliferative and pro-apoptotic
canonical target genes. Importantly, our analyses reveal a
role for TP63 in the constitutive maintenance of DNA re-
pair genes, highlighting the importance of defining the TP53
/TP63 network in order to better understand the biological
implication of de-regulationwhich frequently occurs in can-
cer.
MATERIALS AND METHODS
Cell culture
Primary neonatal Human Foreskin Keratinocytes (HFKs)
were isolated as described previously (30) and cultured
in Epilife supplemented with HKGS (GIBCO). HFKs
were transfected with 50 nM siRNA using Lipofectamine
RNAimax transfection agent (Invitrogen) according to
manufacturer’s instructions with siRNA-targeting total
TP63, TP53 or a scrambled control. Cells were passaged 24
h post-transfection and various drug treatments conducted
48 h post-transfection and harvested after a further 24 h
treatment (72 h post-transfection). Cell lines stably expres-
sion shRNA targeting TP53 or a scrambled control were
generated as previously described (30).
Chromatin immuno-precipitation, PCR and ChIP-seq
Chromatin immuno-precipitation was carried out based on
Schmidt et al. (31–33) with the following amendments. Cells
were cross-linked by addition of formaldehyde to a final
concentration of 1% and incubated for 10 min at room tem-
perature. Cross-linking was stopped by addition of glycine
to a final concentration of 0.125 M washed and washed
twice with ice-cold phosphate buffered saline (PBS). Nu-
clei were isolated as described in Schmidt et al. and equiv-
alent of 1 × 106 nuclei/ml of lysis buffer sonicated for 30
cycles (30 s on 30 s off, high power) in a Diagenode Biorup-
tor. Resulting chromatin supplemented with complete pro-
tease inhibitor cocktail (Roche) was incubated with 50 l of
protein-G Dynabeads (Invitrogen) pre-blocked and bound
with 5 g monoclonal antibodies (Santa Cruz; TP63-4A4;
TP53-DO1) and incubated for 16–18 h at 4◦C. ChIPs were
washed five times with 1 ml Radioimmunoprecipitation as-
say buffer (RIPA) buffer and once with 1 ml TE buffer,
eluted incubated overnight at 65◦C to reverse cross-links,
digested with RNAseA (Ambion) and proteinase K (Invit-
rogen) and purified previously described and libraries pre-
pared for sequencing as previously described (26).
Data analysis
Fastq files were generated with Illumina pipeline soft-
ware (CASAVA 1.8.1 using the default chastity base call
thresholds) and subsequently filtered to remove polymerase
chain reaction (PCR) duplicates. Reads were mapped to the
GRCh37/hg19 reference genome using Burrows Wheeler
Alignment (BWA) allowing for gapped alignment andmax-
imum five alignment locations for each read.
MACS peak calling algorithm (version 1.4; P = 1e−5,
shiftsize = 100) (34), used to call peaks comparing to in-
put. Resulting peaks were curated to remove Encode ‘dark
regions’ (Encode Consensus Signal Artifact Regions) and
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spurious peaks (>1000 reads, mostly in centromeric re-
gions) (35). See Supplementary file 7 for library characteris-
tics. Results have been submitted toNCBIGene Expression
Omnibus (36) accession number GSE56640.
Resulting peak .bed files and .bam read files were used
as input for DiffBind (25,37) to derive consensus peaksets
extracted for each ChIP-seq factor/treatment combination
(Figure 1C and E) and to generate heatmaps. Differential
binding analysis was carried out with Diffbind according
to manual using EDGERwith libraries normalized to total
library size.
For visualization IGVtools (38) from command line was
used to generate .wig files, which were subsequently nor-
malized (per 10 million reads) using wigreader (https://
github.com/rgejman/wigreader) and visualized using the In-
tegrative Genomics Viewer (38). Sitepro tool within Cis-
regulatory Element Annotation System (CEAS) (39) was
used to generate intensity profiles from normalized .wig
files and outputs visualized within R environment (www.
r-project.org).
Read counts across binding sites were generated using
custom scripts (G. Brown, personal communication) and
heatmaps visualized using Java TreeView (40).
To generate de novomotifs,Meme-ChIP (41) analysis was
conducted on 500 bp sequences surrounding peak centre for
peaksets (5000 randomly selected peaks if number greater).
Conservation plots for the 3 kb regions surrounding the
7574 TP63 peaks was generated by plotting PhastCons for
vertebrates using the conservation plot tool fromCEAS (39)
within the Cistrome (42) galaxy environment.
To correlate TP63 and TP53 peaks with potential target
genes, we chose to annotate each peak to any gene within 25
kb of the identified peak. This was achieved by overlapping
peaks with Refseq genes, transcription start sites (TSS) or
termination sites extended by 25 kb downloaded from the
University California Santa Cruz (UCSC) browser (43,44)
within the Galaxy environment (45,46). In addition, peaks
weremapped to genomic features using the CEAS tool from
command line (27,47)
Seqminer (Version 1.3) (48) was used to extract histone
modification data fromEncode data for normal human epi-
dermal keratinocytes (NHEKs) (49,50) and K-means clus-
tering (raw) of this data carried out for respective sets of
binding sites.
Gene ontology analysis was conducted usingDAVID (32)
and terms summarized using REVIGO (31).
RNA extraction and quantitative RT-PCR
RNA extraction was carried out using Trizol (Invitrogen)
according to the manufacturer’s instructions. For quantita-
tive RT-PCR, RNAwas reverse transcribed to cDNA using
the transcriptor high-fidelity cDNA synthesis kit (Roche),
with random hexamers according to the manufacturer’s in-
structions. Amplification of PCR products was monitored
using Lightcycler 480 SYBR Green I Master (Roche) ac-
cording to the manufacturer’s instructions and fluorescence
monitored on a Roche 480 Lightcycler and melting curve
analysis also performed. In brief, cDNA samples were di-
luted 1:50 and quantified compared to a standard dilution
series using the absolute relative quantitation method. The
cycling conditionswere as follows: initial denaturation 95◦C
for 10 min 45 cycles of 95◦C, 15 s; 58◦C, 15 s; 72◦C, 20
s. Expression levels were assessed in triplicate, normalized
to RPLPO and 18S control levels (for primer sequences see
Supplementary file 8). Primers for TP53 and TP63 isoforms
are previously published (25).
Microarray analysis
For microarray analysis RNA was further purified using
RNAeasy columns (Qiagen) according to manufacturer’s
instructions, before submission to Almac Diagnostics for
analysis on the Affymetrix Exon ST 1.0 array platform.
Resulting .cel files were imported into Altanalyze soft-
ware (43) and analysed using default settings. Gene expres-
sion was summarized at an individual gene level for ‘con-
stitutive’ exons (probe sets aligning to those exons regions
most common amongst all transcripts) filtering for probes
with DABG P < 0.05 or expression <1. Fold change and
log2 fold change for all samples was then calculated by com-
paring each sample relative to the mean of the no siRNA
and scrambled untreated controls. Results have been sub-
mitted to NCBI Gene Expression Omnibus (36) accession
number GSE56640.
For head and neck squamous cell carcinoma (HNSCC)
array analysis raw .cel files were downloaded for Thurlow
et al. from MIAME-VICE (http://bioinformatics.picr.man.
ac.uk/vice/Welcome.vice) (51) and for Pyeon et al. (52) from
NCBI Gene Expression Omnibus (GSE8791). Raw data
was imported with RMA normalization into Partek Ge-
nomics Suite (Partek R© software. Copyright, Partek Inc.,
St Louis, MO, USA). Batch effects were removed and dif-
ferential gene expression comparing tumour with normal
was determined using a three-way ANOVA model incor-
porating tumour/normal, site and HPV status (Thurlow
et al. p16 staining, Pyeon et al. HPV microarray hybridiza-
tion). Pyeon et al. included 14 normals and 40 HNSCC
cases. Data from Thurlow et al. was pre-filtered to remove
duplicates and retain only samples from only oral cavity,
oropharynx and larynx (75 total arrays including 13 nor-
mals).
Hypergeometric distribution was used to calculate signif-
icance of genelist overlaps (53), which predicts the probabil-
ity of the overlap of the two gene lists, given the length of
the two lists and the number of genes that could have been
present on both lists (R-code available on request).
Western blot analysis
Western blots were carried out as previously described
(25). Primary antibodies used were Santa Cruz mono-
clonal anti-TP63 (4A4), TP53 (DO1), CDKN1A (C19),
FANCD2 (FL17), polyclonal TP53-pS15 (Cell Signalling),
TP53-pS46 (Abcam), BRCA1 (Sigma prestige), beta-actin
(Sigma), RRM2B (Abcam). Secondary antibodies used in
this study were goat anti-mouse and rabbit-HRP (Santa
Cruz). Luminescencewas revealed by incubationwithWest-
ern Lightning ECL (Perkin-Elmer) and signal detected on
an Alpha Innotech FluorChemTM SP imaging system.
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Figure 1. ChIP-seq analysis of TP53 and TP63 in untreated, adriamycin and cisplatin treated keratinocytes. (A) Normalized ChIP-seq biological replicate
binding profiles around canonical TP53/TP63 target genes CDKN1A and MDM2, in the presence and absence of genotoxic agents adriamycin (350 nM)
and cisplatin (25 M). (B) Clustering of TP53 and TP63 ChIP-seq samples based on binding strength to sites identified using MACS in more than one
sample compared using the Diffbind bioconductor package. (C) Venn diagram illustrating overlap of consensus TP53 peaksets present in both biological
replicates. Where binding sites overlap with more than one site in other treatment sites are merged in Venn diagram. (D) Heatmap of individual TP53
binding sites, centred on peak maximum ± 5 kb. Clustered based on subsets of peaks identified in (C) as illustrated by bars. (E) Venn diagram illustrating
overlap of consensus TP63 peaksets present in both biological replicates. (F) Heatmap of individual TP63 binding sites, centred on peak maximum ± 5
kb. Clustered based on subsets of peaks identified in (E) as illustrated by bars.
Indirect immunofluorescence
Cells were transfected with siRNAs as above and plated
onto coverslips 24 h post-transfection, after a further 24
h coverslips were exposed to 2 Gy ionizing radiation (IR).
Cells were fixed with 4% paraformaldehyde at the indicated
time points, permeabilized in 0.1% Triton X-100/PBS and
blocked in 10% foetal bovine serum/PBS. Cells were stained
for  -H2AX (Millipore) and 53BP1 (Millipore), anti-TP63
(4A4, Santa Cruz), TP53 (DO1, Santa Cruz), primary an-
tibodies overnight at 4◦C, washed and stained with goat
anti-rabbit Alexafluor 488 or anti-mouse 568 Fab′2 frag-
ment secondary antibodies (LifeTechnologies) washed and
mounted in Prolong Gold (LifeTechnologies) containing
4′,6-diamidino-2-phenylindole (DAPI) to visualize nuclei.
Cells were visualized and foci counted using aNikonEclipse
Ti fluorescence microscope, using a ×60 objective.
FACS analysis
Cells were fixed and stained for PI as previously described
(54) and analysed for PI content on a Becton Dickinson
LSR flow cytometer.
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RESULTS
Genome-wide characterization of TP53 and TP63 cistromes
in response to genotoxic stress
To investigate the genome-wide interplay betweenTP53 and
TP63 binding sites, we used primary neonatal HFKs as an
exemplar of epithelial cells and which express high levels
of TP63 and wild-type TP53. HFKs express high amount
of NTP63, predominantly the  C-terminal variant (25),
but undetectable levels of the TA isoforms, while they ex-
press high levels of full length TP53 (Supplemental Fig-
ure S1A). Genome-wide TP53 and TP63 binding sites were
mapped using ChIP-seq validated antibodies, which recog-
nize all isoforms of TP63 and TP53 (Supplementary Fig-
ure S1A) (26,29,55,56) in two independent sets of primary
HFKs, in the presence and absence of genotoxic agents cis-
platin and adriamycin for 24 h. This timeframe resulted in
maximal TP53 stabilization (Supplementary Figure S1B),
binding and activation of target genes such as CDKN1A
(Supplementary Figure S1C and D), but with only mod-
est effects on cell cycle (Supplementary Figure 1E). Activa-
tion is through stabilization of canonical full-length TP53
isoform TP53 (Supplementary Figure S1A, B and G) and
strong serine-15 phosphorylation and to a lesser extent on
serine-46 (Supplementary Figure S1B). This TP53 activa-
tion is concomitant with reduced levels of TP63 protein and
mRNA (Supplementary Figure S1A, B and F), which is
greater at the protein level following adriamycin treatment
(Supplementary Figure S1A) than in cisplatin treated cells.
Visual inspection of normalized binding profiles around the
canonical CDKN1A and MDM2 promoters (Figure 1A)
and clustering based on global occupancy and intensity of
binding demonstrates the reproducibility between replicates
(Figure 1B).
To generate robust consensus peaksets, we consid-
ered only peaks detected in both replicates of each
ChIP/treatment combination using theMACSpeak-calling
algorithm (34) (Supplementary Figure S2). Based on these
criteria, we cumulatively identified a total of 12 287 TP53
sites (Figure 1C and D) (merged from 12 378 total) and 25
858 TP63 sites (Figure 1E andF). Both TP53 andTP63 sites
are highly conserved and enriched for a similar de novoTP53
family motif broadly focused around Refseq TSS (Supple-
mentary Figure S3). This enrichment of TP63 and TP53
around TSS is further supported by more detailed analy-
sis of genomic location of subsets of sites identified in each
of the treatment antibody combinations measured (Supple-
mentary Figure S3D and E). This indicates that constitutive
TP63 and TP53 sites in cells treated with genotoxic agents
are highly enriched in 5′UTRs, bi- and uni-directional pro-
moters.
Comparison of the subsets of peaks identified in different
treatment conditions reveals 2962 TP53 sites constitutively
bound by TP53 in untreated HFKs. The number identified
increases concomitant with TP53 stabilization to 6745 sites
upon adriamycin treatment and to 11 560 upon cisplatin
treatment (Figure 1C and D and Supplementary file 2). In
contrast, a large proportion of TP63 binding events are de-
tected in untreated cells (Figure 1E and F), the majority of
which are lost upon adriamycin treatment (Figure 1E and F
and Supplementary file 2), concomitant with a decrease in
TP63 levels (Supplementary Figure S1A). Somewhat, sur-
prisingly, upon cisplatin treatment a large proportion of
TP63 peaks are still detected (Figure 1E and F), implying
that despite a decrease in TP63 protein levels and binding,
‘occupancy’ is affected to a lesser extent than adriamycin
treatment.
Taken together, this suggests that differential dynamics of
TP53 and TP63 binding depend on nature and intensity of
genotoxic stress.
Comparison of TP53 and TP63 cistromes reveals overlapping
and distinct binding sites
To determine the extent of overlap between TP53 and
TP63 cistromes, we first overlapped our pooled consensus
TP53/TP63 binding sites (Figure 2A). This indicates that
the majority of TP53 sites (9113) are also bound by TP63
in at least one of the conditions measured, whereas the con-
verse is not true for TP63, where more than half the sites are
not bound by TP53 (Figure 2A). To robustly define TP53
and TP63 only bound sites, peaks present in any individual
sample were further subtracted from the non-overlapping
16 745 TP63 or 3174 TP53 consensus peaks to identify 12
054 unique peaks bound only by TP63 and 2042 bound
only by TP53 (Figure 2A). This is illustrated by global (Fig-
ure 2B) and individual (Figure 2C and D) signal intensity
profiles and by sites associated with the JAG2, RHOC and
RRM2B genes, respectively (Figure 2E). Examination of the
average strength indicates that binding of both TP53 and
TP63 is highest for those sites, which can be bound by both
TP53 and TP63 (Figure 2B). The robustness of the peak-
sets is supported by de novo motif analysis, which identifies
enrichment for a TP53/TP63-like binding motif in the ma-
jority of each of these subsets of binding sites. Specifically,
a canonical TP53/TP63 motif is detected centrally, within
76% of TP53/TP63 overlapping peaks (Figure 2F and Sup-
plementary Figure S4). A similar but distinct de novo mo-
tif is present in 74% of TP63 unique peaks (Figure 2F and
Supplementary Figure S4), whereas a more degenerate mo-
tif a highly conserved half site is associated with 68% of
TP53 unique sites (Figure 2F and Supplementary Figure
S4). Further analysis revealed that one TP53 half site motif
(CxxG) is enriched for in 83, 87 and 78% of the overlapping
and TP63 and TP53 unique peaksets, respectively (Sup-
plementary Figure S4). The more highly conserved bind-
ing motifs observed in TP63 and TP63/TP53 overlapping
sites correlates with greater conservation than TP53 only
sites (Supplementary Figure S5A). While all sites localize
broadly to areas surrounding Refseq TSS (Supplementary
Figure S5B), the TP53 only sites are more frequently lo-
cated in proximal promoter regions associated with high hi-
stone H3K4Me3 in cycling NHEKs (ChIP-seq data avail-
able from the ENCODE project (35)), whereas TP63 only
sites are more frequently associated with enhancer-like re-
gions associated with high histone H3K4me1 (Supplemen-
tary Figure S6A) (47). Furthermore, stratification of TP53
and TP63 based on nearest Refseq TSS reveals that as an-
ticipated TP53 and TP63 distal sites (5–25 and >5 kb) are
more frequently associated enhancer-like marks in NHEK
cells, whereas more proximal binding events (<5 kb) are as-
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Figure 2. TP53 and TP63 bind to overlapping and distinct subsets of binding sites. (A) Venn diagram illustrating the overall number of sites bound by
both TP53 and TP63 in any of the conditions tested. TP53 unique sites (2042) were identified as those present in both replicates of any condition, but
not present in any TP63 sample and the converse true for the 12054 TP63 unique sites. (B) Plot of normalized binding intensity across the TP63 unique,
overlapping and TP53 unique sites for TP63 and TP53 across the three treatment conditions. (C and D) Heatmaps of individual TP53 (C) and TP63 (D)
binding sites, centred on peak maximum ± 5 kb. Clustered based on subsets of peaks identified as overlapping, TP53 unique and TP63 unique sites. (E)
Illustrative examples of ChIP-seq results for TP63 unique, overlapping and TP53 unique sites. (F) De novomotifs identified from analysis of TP63 unique,
overlapping and TP53 unique sites.
sociated more frequently as expected with promoter associ-
ated histone marks (Supplementary Figure S6B).
Differential binding analysis reveals differences in
TP53/TP63 binding dynamics in response to different
genotoxic agents
Comparison of normalized TP53 signal intensity across all
12 287 TP53 sites reveals that, similar to occupancy-based
analyses, TP53 binding is increased to the greatest extent
following cisplatin treatment (Figure 3A). The significance
of these differences is supported by differential binding
analysis (37) which identifies 14 332 sites exhibiting a sig-
nificant increase in TP53 binding following cisplatin treat-
ment compared with untreated cells (FDR< 0.1). This is in
comparison to a significant increase of only 6973 sites upon
adriamycin treatment (Figure 3B). Taken together, these re-
sults indicate that there is a greater increase in the number
of sites bound by TP53, and with greater intensity, after
cisplatin treatment compared with adriamycin treatment.
The converse is true for TP63, where global TP63 binding
is decreased more dramatically upon adriamycin treatment
than cisplatin (Figure 3C). This is supported by differential
binding analysis, which reveals that TP63 binding is signif-
icantly decreased by >25 000 sites when comparing adri-
amycin treatment with untreated cells and only 7396 TP63
sites significantly reduced upon cisplatin treatment (Figure
3D).
These quantitative analyses, support differing modes of
regulation utilized by TP53 in response to adriamycin and
cisplatin treatment. By subtractive analysis, we can in fact
discern peaks induced specifically by cisplatin (2184), adri-
amycin (326) or 3868 overlapping damage-induced TP53
binding events each of which is significantly enriched for
de novo TP53-like binding motifs or half sites (Figure 3E–
H). This highlights that not only do these different types of
stress elicit different global effects on TP53 dynamics, but
also that there are damage-induced sites, which are specific
to each type of DNA lesion/agent. In contrast, similar sub-
tractive analysis reveals that only 182 and 10 TP63-specific
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Figure 3. Characterization of differential TP53/TP63 binding dynamics in response to adriamycin or cisplatin treatment. (A) Normalized TP53 binding
intensity across all TP53 in untreated HFKs or following adriamycin or cisplatin treatment. (B) Differential TP53 binding site analysis. log2 concentration
plots of pairwise comparisons of mean normalized read count. Significant changes in bound sites indicated in red (FDR < 0.1). (C) Normalized TP63
binding intensity across all TP53 in untreated HFKs or following adriamycin or cisplatin treatment. (D) Differential TP63 binding site analysis. log2
concentration plots of pairwise comparisons ofmean normalized read count. Significant changes in bound sites indicated in red (FDR< 0.1). (E) Illustrative
examples of ChIP-seq results for TP53 adriamycin only, cisplatin only and overlapping sites induced upon genotoxic stress. (F) Normalized TP53 binding
intensity across adriamycin only, cisplatin only and overlapping TP53 sites induced upon genotoxic stress. (G) Plot of normalized binding intensity across
all of the TP63 and TP53 sites for each of the three treatment condition. (H) Summary of de novo motif analysis of adriamycin only, cisplatin only and
overlapping sites damage-induced TP53 sites.
new binding events are detected subsequent to cisplatin and
adriamycin treatments, respectively (data not shown) re-
enforcing the fact that the vast majority of TP63 sites are
detected in cycling cells.
Characterization of global effects on transcription mediated
by TP53 and TP63 in response to genotoxic stress
To identify genes whose expression could be influenced by
the TP53 and TP63 cistromes, we first annotated peaks to
REFSEQ genes identifying 9087 and 13 403 genes within
25 kb of a TP53 or TP63 binding event respectively regard-
less of treatment (Supplementary Figure S7, Supplemen-
tary file 1 and Supplementary file 3). Therefore, TP53 and
TP63 have the potential to directly influence expression of a
large proportion of the genome. This threshold was initially
chosen since data from our laboratory and others has re-
vealed potential for regulatory events to occur inmore distal
regions for TP63, TP53 and other factors such as estrogen
receptor (26,55,57).
To gain a global perspective of the downstream effects
of these binding events we integrated binding data with
mRNA expression data generated by exon-array profiling,
carried out concomitantly with one of the ChIP-seq repli-
cates. Specifically, the same batch of HFKs cells were trans-
fected with siRNA targeting TP53, TP63, scrambled con-
trol or untreated control. These cells were then treated in
parallel with the cells used for ChIP-seq with cisplatin or
adriamycin for 24 h and RNA extracted and submitted for
Affymetrix Exon Array analysis. Results were analysed us-
ing the Altanalyze software package (43) at an individual
gene level by combining results for constitutively spliced ex-
ons. Fold change in response to treatment was then calcu-
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lated by comparing adriamycin or cisplatin treatment rela-
tive to the mean of the no siRNA and scrambled untreated.
Using this strategy, we identify 1563 and 1153 genes in-
duced at least 1.7-fold by adriamycin or cisplatin treatment,
respectively (Supplementary Figure S8A and Supplemen-
tary file 4). In both treatments, induction of a significant
proportion of these genes (700 adriamycin and 463 cis-
platin) was prevented in TP53 siRNA depleted cells (1.5-
fold change in opposite direction) (Supplementary Figure
S8), indicating that this induction is TP53-dependent. A
highly significant proportion of these genes (Figure 4A
and B and Supplementary file 5) (599, hypergeometric
P< 1e−16) are also within 25 kb of 961 TP53 binding sites,
potentially representing direct TP53-induced target genes
(Figure 4B and C), many of which, such as CDKN1A, are
associated with multiple TP53 sites.
A significant subset (219) of these TP53-induced genes
are within 25 kb of constitutive TP53 binding sites in un-
treated cells, 123 of these sites are also associated with at
least one additional DNA-damage-induced TP53 site (Fig-
ure 4C and Supplementary Figure S9A), while an addi-
tional 380 induced genes are associated with sites only de-
tected upon damage. These 599 damage-induced genes are
enriched, for TSS/promoter proximal TP53 binding events
as opposed to 3-prime binding at TTS (Figure 4D and Sup-
plementary Figures S3D and E and S8B). Together, this
implies complex modes of activation of TP53 target genes,
through increased binding or activation of sites already
bound by TP53 and/or induction of TP53 binding to novel
sites. The intricacy of these regulatory events is highlighted
by the presence of multiple TP53/TP63 binding sites at var-
ious distances relative to the TSS of both induced and re-
pressed genes (Supplementary Figure S9C and D).
These analyses are complicated by the presence of TP63
on the majority of TP53 sites (Figure 4C), which potentially
influences TP53 activity through transcriptional inhibition
and/or competitive binding. As such, we also observe sig-
nificant enrichment for pooled TP63 binding sites within 25
kb of induced genes (Figure 4B and Supplementary Figure
S8A, Supplementary file 1 and Supplementary file 4). Most
of these genes are associated with sites bound by both TP53
and TP63 in at least one of the conditions measured (Figure
4C and Supplementary Figure S9B), indicating that these
represent canonical target genes whose activation is induced
by TP53 but opposed in cycling cells by TP63 binding.
Interestingly, the number of genes induced by cisplatin
(195) associated with TP53 binding was significantly less
than that induced by adriamycin (457), (Supplementary
Figure S7), perhaps reflecting the differing binding dynam-
ics and/or biological effects of the doses and time points
chosen (Supplementary Figure S1). Cumulatively, these 772
TP53-damage-induced targets associatedwith TP53 and/or
TP63 binding (Figure 4B) are enriched for genes involved
in apoptosis, cell cycle arrest, DNA damage and stress re-
sponse (Figure 4E and Supplementary Figure S9A).
Significantly, using the same selection criteria, both geno-
toxic agents resulted in repression of a greater number of
genes in a TP53-dependent manner, a large proportion of
which (1362) were also within 25 kb of a TP53 site, con-
sidering both genotoxic agents (Figure 4F and Supplemen-
tary Figure S8A, Supplementary file 4). In contrast to in-
duced genes, TP53 sites associated with repressed genes are
not enriched in promoter proximal regions (Figure 4H),
rather they are associated with de novo damage-dependent
events at more distal binding sites (Supplementary Figure
S9E). This was particularly apparent for cisplatin treat-
ment, which resulted in TP53-dependent down-regulation
of a larger total number of genes (1160) than associated
with adriamycin treatment (557) (Supplementary Figure
S7). Like induced genes, the majority of TP53 sites within
25 kb of repressed genes are also bound by TP63 in one of
the conditions measured (Figure 4G). Importantly, a highly
significant number of TP63-specific binding events occur
within 25 kb of TP53-dependent repressed genes (Figure
4G and Supplementary Figure S9F), suggesting that that
TP53 can negatively regulate expression of a subset of genes
through affecting TP63 transcriptional activity, DNA bind-
ing, protein levels or a combination thereof. In fact, ex-
pression array data indicates that TP63 depletion alone is
sufficient to result in down-regulation of a subset of these
genes that are repressed after DNA damage in a TP53-
dependent matter (Figure 4A and Supplementary Figure
S10). Collectively, the 2236 (Figure 4F) genes we identify
as being repressed in a TP53-dependent manner and asso-
ciated with TP53/TP63, TP63 only or TP53 only binding
sites are highly enriched for genes involved in cell cycle pro-
gression, DNA metabolism and repair (Figure 4I and Sup-
plementary Figure S10).
Our global analyses indicate that TP53 can positively
and negatively influence the expression of a large number
of genes in response to DNA damage and that TP63 po-
tentially plays an important role in regulating these events.
Specifically, our results suggest that activation events are
likely mediated directly by TP53, through a combination of
increased binding, activation of pre-bound protein, or loss
of repression mediated by TP63.
Furthermore, analysis of all TP53 and TP63 sites asso-
ciated with induced genes indicates they have higher levels
of H3K4me3 in NHEK cells (35), indicative of promoter-
like elements (47), whereas sites associated with repressed
genes have low H3K4me3 and high H3K4me1 levels, in-
dicative of enhancer-like elements (Supplementary Figure
S11). Therefore, TP53 potentially elicits its suppressive ef-
fect through modulation of enhancer activity, which is con-
stitutively bound by TP63.
TP53 and TP63 interplay in regulating DNA damage repair
genes
Our global findings suggest a complex interplay between
TP53 and TP63 resulting in a number of potential modes
of regulation, dependent on the individual gene and the
type and intensity of genotoxic stress. We next sought
to validate these different modes of co-regulation of spe-
cific target genes. Interestingly, gene ontology analyses,
indicated significant enrichment for TP53-dependent re-
pression and induction of genes, involved in DNA dam-
age response (Figure 4E and I and Supplementary Figure
S10). These included genes encoding proteins involved in
homologous recombination (HR)/Fanconi Anemia (FA)
pathway (RAD51B, BRCA1, FANCD2, BRCA2), Non-
Homologous end Joining (e.g. XRCC4) and mismatch
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Figure 4. Integration of ChIP-seq and microarray data reveals complex interplay between TP53 and TP63. (A) Heatmap of microarray data showing TP53
and TP53/TP63 and TP63 bound genes. (B) Comparison of genes induced in a TP53-dependent manner upon either adriamycin or cisplatin treatment
with those within TP53 and TP63 binding sites identifies 772 potential target genes. (C) Analysis of TP53 and TP63 sites within 25 kb of 772 induced genes
from (B) superimposed with genes associated with TP53 binding in untreated cells. (D) Histogram comparing distance of TP53 sites from transcription
start sites (TSS) and transcription termination sites (TTS) of 772 induced genes. (E) Gene ontology analysis of 772 induced genes. (F) Comparison of
genes repressed in a TP53-dependent manner upon either adriamycin or cisplatin treatment with those within TP53 and TP63 binding sites identifies 2236
potential target genes. (G) Analysis of TP53 and TP63 sites within 25 kb of 2236 repressed genes from (F) superimposed with genes associated with TP53
binding in untreated cells. (H) Histogram comparing distance of TP53 sites from TSS and transcription termination sites of 772 induced genes. (I) Gene
ontology analysis of 2236 repressed genes identified.
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repair (e.g. MSH2) (Figure 5A). We also observed up-
regulation of components of the nucleotide excision repair
pathway (XPC, DDB2) and DNA damage responsive nu-
cleotide biosynthesis (RRM2B), which have been previ-
ously identified as TP53 targets (58,59). We chose to vali-
date a subset of these repair genes/proteins associated with
different potential modes of regulation. Specifically, we ex-
amined: (i) induced genes (RRM2B, DDB2 and XPC) as-
sociated with both TP53 and TP63 binding; (ii) repressed
genes associated with both TP53/TP63 sites (RAD51B,
MSH2 and XRCC4) and (iii) those with TP63 binding only
within 25 kb (BRCA1, BRCA2 and FANCD2) (Figure 5A).
Validation of these promoter proximal events by quan-
titative ChIP-PCR (qChIP-PCR) correlates with ChIP-seq
results, with induced binding of TP53 to RRM2B and
DDB2 promoters and a weaker binding to the XPC pro-
moter (Figure 5B). Interestingly, binding of TP63 to all of
these TP53 bound sites was also observed in untreated cells
(Figure 5B and Supplementary Figure S12A and B) and
decreased, particularly upon adriamycin treatment (Figure
5B). To correlate binding events with effects on gene ex-
pression, we conducted RT-PCR (qRT-PCR) from primary
HFKs transiently depleted for TP53 or TP63 in the presence
or absence of adriamycin or cisplatin treatment and con-
firmed effects on CKDN1A expression as a positive con-
trol (Figure 5C). TP53 depletion results in attenuation of
induction of DNA repair genes RRM2B, DDB2, XPC and
the positive control CKDN1A (Figure 5C and D). These
effects are titratable at both the mRNA and protein level
(Figure 5E and Supplementary Figure S13). Depletion of
TP63 alone is sufficient to increase levels of RRM2B and
CDKN1A, implying that TP53 activity is repressed byTP63
in the absence of genotoxic stress (Figure 5C).
In contrast to induced genes, TP53 binding events asso-
ciated with gene repression are more frequently new bind-
ing sites upon genotoxic stress (Supplementary Figure S9A
and D) and are less strongly bound as measured by fold en-
richment and peak height (RAD51B, MSH2 and XRCC4)
(Figure 5F and Supplementary Figure S12C–E, Supple-
mentary file 1). Quantitative RT-PCR in transiently TP53
or TP63 depleted HFKs confirms that down-regulation of
RAD51B, MSH2 and XRCC4 occur in a TP53-dependent
manner in both transiently and stably TP53 depleted cells
(Figure 5G and Figure S13C–E). Unlike, TP53-induced
genes TP63 depletion alone did not effect mRNA expres-
sion ofRAD51B,MSH2 orXRCC4 (Figure 5G), indicating
that a genotoxic signal is required to activate these events.
Interestingly, TP63 mRNA and protein levels were both
observed to be reduced in a TP53-dependent manner upon
adriamycin and cisplatin treatment since TP53 depletion re-
sulted in higher expression of TP63 (Figure 5C and Sup-
plementary Figure S13). In support of an interaction be-
tween TP53 and TP63 expression, our global analyses re-
vealed a significant enrichment for genes associated with
TP63 only binding as being repressed in a TP53-dependent
manner in response to genotoxic treatment (Figure 4F and
Supplementary Figure S8A, Supplementary file 4). Inter-
estingly, within the DNA repair associated subset we no-
ticed a number of core effectors of homologous recombina-
tion (BRCA1, BRCA2 and FANCD2) that exemplified this
interaction (Figure 5F and H and Supplementary Figure
S12F–H). As predicted from our expression array results
(Figure 5A), quantitative RT-PCR confirmed that not only
are these genes repressed in a TP53-dependent manner in
response to genotoxic stress, but that TP63 depletion alone
was sufficient to significantly reduce expression of BRCA1
and BRCA2 in untreated cells (Figure 5H) suggesting that
TP63 plays a role in maintaining expression of these genes.
TP63 affects repair of double strand breaks in a TP53 inde-
pendent manner
Our results suggest that TP53 can affect expression of DNA
damage repair genes directly and indirectly through influ-
encingTP63 levels and activity. This suggests that TP63may
play a role in maintaining constitutive expression of a sub-
set of these genes, in particular those devoid of TP53 prox-
imal binding events, whilst repressing activation of those
genes constitutively bound by TP53. To test these hypothe-
ses, we assessed constitutive expression levels of DNA dam-
age repair genes upon TP63 depletion in HFK lines sta-
bly depleted of TP53 or scrambled control. Depletion of
TP63 results in constitutive up-regulation of RRM2B and
CDKN1A, which is attenuated in the shTP53 background
(Figure 6A and B). This indicates that as for CDKN1A,
TP63 actively represses the RRM2B promoter in the ab-
sence of genotoxic insult. This is not the case for all TP53-
activated targets, since XPC and DDB2 are not activated
uponTP63 depletion (Figure 6A) and stable TP53 depletion
alone only has a minor effect, implying that a DNA damage
signal is required to activate transcription of these targets.
A similar complexity is observed for repressed genes, associ-
atedwithTP53 andTP63 binding, namelyRAD51B,MSH2
andXRCC4, which are unaffected by TP63 depletion alone.
However, we do observe a modest increase in expression of
these genes in TP53 depleted cells, which is TP63-dependent
(Figure 6A). Importantly, BRCA1, BRCA2 and FANCD2,
which were associated with TP63 binding only, are signif-
icantly decreased upon TP63 depletion in both TP53 pro-
ficient and deficient cells (Figure 6A), implying that TP63
plays TP53 independent roles in their regulation.
If TP63 were involved in constitutively regulating DNA
damage repair genes such asBRCA1 andBRCA2, we would
predict that there is a consequence for the cell when TP63
is depleted. To test this hypothesis, we treated TP63 de-
pleted cells in the presence or absence of TP53 in order
to control for TP53-dependent effects. These cells were
then treated with ionizing radiation to induce DNA double
strand breaks and their ability to resolve this damage moni-
tored by quantification of phospho-gammaH2AX foci over
time. No significant effect on basal number of foci was ob-
served in the absence of IR, however, 24 h post-treatment,
we observed significantly higher numbers of unresolved foci
in TP63 depleted cells regardless of TP53 status (Figure 6C).
Taken together, the results suggest that in the absence of
genotoxic insult TP63 plays a role inmaintaining expression
of genes important for DNA repair, in addition to its role
in preventing spurious activation of TP53-mediated consti-
tutive targets. In addition, we predicted genes that are re-
pressed by TP53 would be up regulated in cancers that har-
bour a TP53 mutation, with high expression of TP63. Head
and neck cancers have a high incidence of mutant TP53
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Figure 5. Characterization of effects of role of TP53 and TP63 in regulation of DNA repair genes. (A) Heatmap of microarray results for selected DNA
damage repair genes. Data expressed as log2 fold change compared with average of untreated controls. (B) Quantification of TP53 and TP63 binding to
regions associated with TP53-dependent induced repair genes XPC, DDB2, RRM2B and positive control CDKN1A by ChIP- followed by quantitative
PCR (qChIP-PCR). (C) Confirmation by qRT-PCR of TP53 and TP63 depletion and effect on expression of CDKN1A positive control in adriamycin or
cisplatin treated HFKs. (D) Quantitation by qRT-PCR of effects of adriamycin or cisplatin treatment on mRNA expression of TP53-dependent induced
DNA repair genes RRM2B,DDB2 andXPC in TP53 and TP63 depletedHFKs. (E)Western blot analysis of TP53, TP63, RRM2B, BRCA1, FANCD2 and
control CDKN1A protein expression in HFKs stably depleted for TP53 in response to treatment with increasing amounts of adriamycin (70 nM/350 nM)
or cisplatin (5 M/25 M). (F) Quantification of TP53 and TP63 binding to regions associated with TP53 dependently repressed repair genes RAD51B,
MSH2, BRCA1 by qChIP-PCR. (G) Quantitation by qRT-PCR of effects of adriamycin or cisplatin treatment on mRNA expression of TP53/TP63 bound
TP53-dependent repressed DNA repair genes RAD51B, MSH2. (H) Quantitation by qRT-PCR of effects of adriamycin or cisplatin treatment on mRNA
expression of TP63 only bound TP53-dependent repressed DNA repair genes BRCA1, BRCA2 and FANCD2. qChIP-PCR show mean ± SD. qRT-PCR
shows mean ± SEM of at least three biological replicates. P-values calculated with Student’s t-test. *P < 0.05; **P < 0.01; ***P < 0.001.
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Figure 6. TP63 plays TP53-dependent and independent roles in basal expression of DNA repair genes. (A) Quantitation by qRT-PCRof effects of transient
siRNA-mediated TP63 depletion on constitutive mRNA expression of DNA repair genes in stably TP53 depleted and scrambled control HFK lines. (B)
Western blot analysis of effects of transient TP63 depletion on expression of RRM2B, CDKN1A, BRCA1 and FANCD2 in stably TP53 depleted and
scrambled control HFK lines. (C) Analysis of effects of transient TP63 depletion on 53BP1/H2AX Foci resolution following treatment with 2 Gy ionizing
radiation (IR) in stably TP53 depleted and scrambled controlHFK lines. qRT-PCR showsmean± SEMof at least three biological replicates. 53BP1/H2AX
results represent the number of cells with >5 foci n >100 cells for three independent replicates. P-values calculated with Student’s t-test. *P < 0.05; **P <
0.01; ***P < 0.001.
(13,50) and high expression of TP63. Therefore, to deter-
mine the biological relevance of our results we interrogated
two gene expression profiling datasets of head and neck can-
cers. This revealed that these cancers express significantly
higher levels of genes (473 and 414) normally repressed by
TP53 and that these up-regulated gene sets are enriched for
genes involved in DNA repair and cell cycle progression
(Supplementary Figures S14 and S5)
In summary, we have carried out ChIP-seq for TP53
and TP63 in primary human keratinocytes before and af-
ter DNA damage and integrated this with microarray data
from the same cells. The data indicate that TP53 is bound to
many fewer sites in cycling cells than TP63, but upon DNA
damage TP63 is replaced by TP53 binding resulting in re-
pression of genes involved in cell cycle, DNA repair and
metabolism.
DISCUSSION
In this study, we describe comprehensive genome-wide
mapping of the interplay between TP53 and TP63 bind-
ing and the effects of different types of genotoxic stress
in primary keratinocytes. These analyses reveal that TP53
and TP63 can bind to overlapping but distinct networks of
binding sites, the specificity of which is determined through
binding to differing TP53-like binding motifs. Importantly,
our results suggest that constitutive TP53 binding sites are
more strongly bound and containmore canonical-like TP53
response elements (TP53-RE), whereas those induced by
 at Institute of Cancer Research on July 11, 2016
http://nar.oxfordjournals.org/
D
ow
nloaded from
 
6282 Nucleic Acids Research, 2014, Vol. 42, No. 10
DNA damage are weaker and more diverse and less well
conserved. This suggests that induced TP53 binding is a dis-
tinct event, which correlates with recent evidence indicating
that co-operative interaction betweenTP53monomers is re-
quired for binding to low affinity sites associated with pro-
apoptotic genes (60) and that this is important for the tu-
mour suppressive capacity of TP53 (61). Furthermore, this
also correlates well with recent data suggesting a two-step
model of TP53 activation mediated through different com-
binations of half-sites (62).
The majority of TP53 sites we identified are bound by
TP63 in untreated cells, irrespective of whether TP53 is con-
stitutively bound or TP53 binding is induced by genotoxic
stress. However, the converse is not true for TP63 sites and
a large proportion of sites are not bound by TP53 in any of
the conditions measured. Surprisingly, comparison of the
changes in TP53 and TP63 binding upon cisplatin and adri-
amycin reveals substantial differences in the dynamics of
both TP53 and TP63 binding, suggesting different mecha-
nisms of regulation. Specifically, cisplatin treatment results
in a substantial increase in both the number of sites and the
amount of TP53 bound compared with adriamycin treat-
ment.
This is in contrast to the effects on TP63 binding, which
is greatly reduced on adriamycin treatment, compared with
cisplatin treatment. Importantly, we also observed a sig-
nificant number of strongly bound constitutive TP53 and
TP63 sites in untreated cells, whereas TP53 sites induced
de novo by genotoxic stress are generally weaker. Interest-
ingly, these constitutive TP53 binding sites include canoni-
cal TP53 target genes CDKN1A, and RRM2B. Addition-
ally, these canonical TP53/TP63 genes are up-regulated
in a TP53-dependent manner in TP63 depleted cells, im-
plying that removal of TP63-mediated repression is suf-
ficient to activate TP53-mediated transcription. Irrespec-
tive of their constitutive or DNA-damage-induced nature,
the majority of TP53 sites associated with DNA-damage-
induced genes are also bound by TP63 in untreated cells
and these are frequently associated with promoter proximal
elements. Our genome-wide analyses identify >500 such
‘canonical’ targets and the results suggest and that >30%
of TP53-dependent DNA damage-activated genes are asso-
ciated with at least one constitutive TP53 binding site. This
suggests that TP53 is pre-bound where it is poised for rapid
activation in response to a stress signal, which is held in
check through repression mediated by TP63 in unstressed
cells.
Interestingly, ATMhas been shown to both activate TP53
through serine-15 phosphorylation (63) and concomitantly
phosphorylate NP63 inactivating and targeting it for
degradation (64). This may explain why we see a prefer-
ence for TP53-induced targets activated in response to adri-
amycin treatment, compared with cisplatin treatment, since
adriamycin is known to be a potent activator of ATM-
mediatedTP53 phosphorylation and concomitant stabiliza-
tion (65), which may be sufficient to induce activation of a
subset of constitutively bound genes. Importantly, TP53 is
not stabilized to a significant extent in TP63 depleted cells,
rather it is phosphorylated on serine-46 a post-translational
modification associated with its transcriptional activation
and also observed in response to adriamycin and cisplatin
in this study. This highlights the importance of extending
these studies to determine the co-factors and mechanisms
involved in determining the transcriptional outcomes of the
TP53/TP63 axis.
Our expression analyses revealed many more genes re-
pressed in a TP53-dependent manner in response to geno-
toxic stress, in particular, to cisplatin treatment. These
effects are likely influenced both directly through TP53-
induced binding and indirectly through downstream effects
of known TP53 targets CDKN1A or E2F7 (66) or indeed
TP63 inactivation as demonstrated here. We did observe
TP53 binding sites frequently associated with more dis-
tal TP53 binding events in enhancer-like elements the ma-
jority of which are associated with TP63 binding in un-
treated cells. Of course, as has now been shown for many
transcription factors, ascribing functional significance of
non-promoter associated binding events is more difficult.
However, in contrast to induced genes, we identify a highly
significant number of genes associated with only TP63
sites within 25 kb that are repressed in a TP53-dependent
manner, suggesting that TP53 may elicit additional effects
throughmodulating TP63 transcriptional activity. This is of
particular interest, sincewe found that TP63mRNAexpres-
sion and protein levels are repressed in a TP53-dependent
manner, concomitant with induced TP53 binding to the
TP63 C40 enhancer region (67). This additional level of
control of TP63 activity by TP53 is particularly desirable
in HFKs and other stratifying epithelia, as these tissues are
exposed to high levels of environmental stress, such as UV
radiation. Intriguingly, the 2236 genes we identify as down
regulated in a TP53-dependent manner are enriched for cell
cycle progression, DNA repair and metabolism, suggesting
that in response to high levels of genotoxic stress TP53 can
directly influence these processes through direct TP53 bind-
ing or indirectly through affecting TP63 activity.
Specifically, our downstream validation reveals novel
roles for TP53 and TP63 in controlling a number of TP53-
dependent DNA damage repressed repair genes. Expres-
sion of these genes is either directly repressed through
TP53 binding (MSH2, XRCC4 and RAD51B) or re-
pressed through a TP53-mediated alteration of TP63 activ-
ity (BRCA1, BRCA2 and FANCD2). This along with our
genome-wide data indicates that in response to high levels
of genotoxic stress TP53 activation results in a transcrip-
tional shut down of a large number of DNA repair proteins
in coordination with repression of cell cycle progression re-
lated genes. These binding events are opposed by TP63 and
interestingly, TP53 repressive events are more frequently as-
sociated with more distal enhancer-like regions, the major-
ity of which are bound byTP63 suggesting that these repres-
sive effects may be influenced throughmodulating enhancer
activity. This may be similar to recently described repres-
sive effects elicited by TP53 binding to enhancer regions to
repress, pluripotency genes in mouse embryonic stem cells
(68).
Intriguingly, we noted that repressed DNA repair genes
associated with only TP63, were enriched for critical regula-
tors of homologous recombination andwe showTP63 plays
a role in the constitutive expression of BRCA1, BRCA2 and
FANCD2 independent of TP53. Consequently, TP63 de-
ficient HFKs are significantly impaired in their ability to
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repair double strand breaks induced by ionizing radiation
irrespective of TP53-dependent effects on proliferation. In
contrast, analyses of the genes identified as TP53-induced
are greatly enriched for apoptosis, inhibition of cell cycle
and epidermal/keratinocyte differentiation. Validation of
these global observations with respect to DNA repair genes
indicates different modes of TP53-mediated activation of a
number of known TP53 activated repair genes (RRM2B,
DDB2 and XPC) (58,59,69), which can be repressed by
TP63.
Interestingly, expression of DNA repair genes BRCA2,
Rad51 andMre11 have recently been shown to be activated
by TP63 and TP73 in mouse embryonic fibroblasts (MEFS)
(70) and it will therefore be important to extend these stud-
ies to other cells types which express a different complement
of TP53 family members. Comparison of our data with re-
cently published TP53 ChIP-seq data indicates significant
overlaps, however, this is hard to interpret owing to the dis-
parate cell types and damaging agents used (Supplementary
Figure S15) (28,29,56,71), highlighting the need for further
comprehensive systematic studies to further dissect the un-
derlying mechanisms.
Together, our analyses reveal that through differential
binding events, TP53 and TP63 coordinate expression of an
extensive network of genes in response to genotoxic stress
resulting in both transcriptional activation and repression.
Loss of these repressive functions of TP53 or its counter-
action through elevated TP63 expression has the poten-
tial to contribute to tumour growth and survival, in ad-
dition to loss of TP53’s tumour suppressive pro-apoptotic
and anti-proliferative functions. In support of this, when we
compared our TP53/TP63 regulated genes with microarray
data from tumours andmatched normal in two independent
head and neck squamous cell carcinoma cohorts (51,52), we
found that there was significant enrichment for increased
expression of genes that are TP53 repressed, whereas no sig-
nificant enrichment was observed for TP53-induced genes.
Importantly, most head and neck cancers contain mutant
TP53 and increased levels of TP63, suggesting that mainte-
nance of expression of these repressed genes is important in
established tumours. In support of this, in a TP53 deficient
mouse model of SCC, TP63 has recently been shown to be
required for tumour survival through expression of FGFR2
(72), which we recently characterized as a TP63 target gene
(26). Furthermore, TP63 repressive role likely extends be-
yond its functional opposition of TP53 target gene expres-
sion as evidenced by a recent study which showed that TP63
can repress target genes through SRCAP-mediated H2AZ
deposition (73).
Using genome-wide approaches, these studies have re-
vealed the scale of the interplay between TP53 and TP63 in
normal HFKs and identified novel mechanisms of regula-
tion, through which TP53 and TP63 coordinately influence
expression of a vast array of genes. However, like most stud-
ies, this one is limited by the fact that we have not consid-
ered the function of TP73. While TP73 is expressed in very
low levels in HFKs, they may be induced under certain con-
ditions and impact functions of TP53 and TP63. However,
our results do provide a framework to extend these anal-
yses to other cellular and physiological settings consider-
ing the context of TP53 family members mutational status,
isoform expression and post-translational modifications to
better determine how this network is de-regulated in can-
cer (reviewed in (74,75)). This is particularly pertinent, since
recent observations have demonstrated that the canonical
transactivation domain of TP53 have been shown to be,
in part, dispensable for its tumour suppressive activity (23)
and that mutant missense forms of TP53 have been shown
to exert ‘gains of function’ through influencing TP63 and
TP73 activity (17–19,76). As a result, a better understand-
ing of how the TP53 family functions as a whole is critical
for targeting this pathway in cancer.
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Supplementary Data are available at NAR Online.
ACKNOWLEDGEMENTS
We are thankful to Gordon Brown and Rory Stark for ad-
vice with DiffBind and scripts, and Paul Mullan, Dan Lon-
gley, Richard Kennedy and Kienan Savage for reviewing
manuscript.
Authors’ contributions: S.S.M., D.P. and D.J.M. designed all
experiments. S.S.M., D.P. and M.M. performed experimen-
tal work. S.S.M., I.K., K.F. and J.C. carried out ChIP-seq
analyses. S.S.M. and N.J.O. carried out statistical analyses.
S.S.M., D.P., C.J.L., A.A. and D.J.M. contributed to the
interpretation of the data. The manuscript was written by
S.S.M., D.J.M. with the help from other authors. All au-
thors read and approved the final manuscript.
ACCESSION NUMBER
NCBI Gene Expression Omnibus accession number:
GSE56640.
FUNDING
Medical Research Council (MRC) project [G0700754,
G1001692]; Breakthrough Breast Cancer. Funding for open
access charge: MRC grant.
Conflict of interest statement.None declared.
REFERENCES
1. McDade,S.S. and McCance,D.J. (2010) The role of p63 in epidermal
morphogenesis and neoplasia. Biochem. Soc. Trans., 38, 223–228.
2. Murray-Zmijewski,F., Lane,D.P. and Bourdon,J.-C. (2006)
p53/p63/p73 isoforms: an orchestra of isoforms to harmonise cell
differentiation and response to stress. Cell Death Differ., 13, 962–972.
3. Yang,A., Schweitzer,R., Sun,D., Kaghad,M., Walker,N.,
Bronson,R.T., Tabin,C., Sharpe,A., Caput,D., Crum,C. et al. (1999)
p63 is essential for regenerative proliferation in limb, craniofacial and
epithelial development. Nature, 398, 714–718.
4. Donehower,L.A., Harvey,M., Slagle,B.L., McArthur,M.J.,
Montgomery,C.A., Butel,J.S. and Bradley,A.S.S. (1992) Mice
deficient for p53 are developmentally normal but susceptible to
spontaneous tumours. Nature, 356, 215–221.
5. Malkin,D., Li,F.P., Strong,L.C., Fraumeni,J.F., Nelson,C.E.,
Kim,D.H., Kassel,J., Gryka,M.A., Bischoff,F.Z. and Tainsky,M.A.
(1990) Germ line p53 mutations in a familial syndrome of breast
cancer, sarcomas, and other neoplasms. Science, 250, 1233–1238.
6. Mills,A., Zheng,B., Wang,X., Vogel,H. and Roop,D. (1999) p63 is a
p53 homologue required for limb and epidermal morphogenesis.
Nature, 398, 708–713
 at Institute of Cancer Research on July 11, 2016
http://nar.oxfordjournals.org/
D
ow
nloaded from
 
6284 Nucleic Acids Research, 2014, Vol. 42, No. 10
7. Brunner,H.G., Hamel,B.C.J. and Bokhoven Hv,H.V. (2002) P63 gene
mutations and human developmental syndromes. Am. J. Med. Genet.,
112, 284–290.
8. el-Deiry,W.S., Kern,S.E., Pietenpol,J.A., Kinzler,K.W. and
Vogelstein,B. (1992) Definition of a consensus binding site for p53.
Nat. Genet., 1, 45–49.
9. Riley,T., Sontag,E., Chen,P. and Levine,A. (2008) Transcriptional
control of human p53-regulated genes. Nat. Rev. Mol. Cell. Biol., 9,
402–412.
10. Scheffner,M., Takahashi,T., Huibregtse,J.M., Minna,J.D. and
Howley,P.M. (1992) Interaction of the human papillomavirus type 16
E6 oncoprotein with wild-type and mutant human p53 proteins. J.
Virol., 66, 5100–5105.
11. Bulavin,D.V., Demidov,O.N., Saito,S., Kauraniemi,P., Phillips,C.,
Amundson,S.A., Ambrosino,C., Sauter,G., Nebreda,A.R.,
Anderson,C.W. et al. (2002) Amplification of PPM1D in human
tumors abrogates p53 tumor-suppressor activity. Nat. Genet., 31,
210–215.
12. Momand,J., Zambetti,G.P., Olson,D.C., George,D. and Levine,A.J.
(1992) The mdm-2 oncogene product forms a complex with the p53
protein and inhibits p53-mediated transactivation. Cell, 69,
1237–1245.
13. Stransky,N., Egloff,A.M., Tward,A.D., Kostic,A.D., Cibulskis,K.,
Sivachenko,A., Kryukov,G.V., Lawrence,M.S., Sougnez,C.,
McKenna,A. et al. (2011) The mutational landscape of head and neck
squamous cell carcinoma. Science, 333, 1157–1160.
14. Buckley,N.E., Conlon,S.J., Jirstrom,K., Kay,E.W., Crawford,N.T.,
O’Grady,A., Sheehan,K., Mc Dade,S.S., Wang,C.-W., McCance,D.J.
et al. (2011) The DeltaNp63 proteins are key allies of BRCA1 in the
prevention of basal-like breast cancer. Cancer Res., 71, 1933–1944.
15. Urist,M.J., Di Como,C.J., Lu,M.-L., Charytonowicz,E., Verbel,D.,
Crum,C.P., Ince,T.A., McKeon,F.D. and Cordon-Cardo,C. (2002)
Loss of p63 expression is associated with tumor progression in
bladder cancer. Am. J. Pathol., 161, 1199–1206.
16. Tucci,P.P., Agostini,M.M., Grespi,F.F., Markert,E.K.E.,
Terrinoni,A.A., Vousden,K.H.K., Muller,P.A.J.P., Do¨tsch,V.V.,
Kehrloesser,S.S., Sayan,B.S.B. et al. (2012) Loss of p63 and its
microRNA-205 target results in enhanced cell migration and
metastasis in prostate cancer. Proc. Natl. Acad. Sci. U.S.A., 109,
15312–15317.
17. Adorno,M., Cordenonsi,M., Montagner,M., Dupont,S., Wong,C.,
Hann,B., Solari,A., Bobisse,S., Rondina,M.B., Guzzardo,V. et al.
(2009) A Mutant-p53/Smad complex opposes p63 to empower
TGFbeta-induced metastasis. Cell, 137, 87–98.
18. Muller,P.A.J., Caswell,P.T., Doyle,B., Iwanicki,M.P., Tan,E.H.,
Karim,S., Lukashchuk,N., Gillespie,D.A., Ludwig,R.L., Gosselin,P.
et al. (2009) Mutant p53 drives invasion by promoting integrin
recycling. Cell, 139, 1327–1341.
19. Lang,G.A., Iwakuma,T., Suh,Y.-A., Liu,G., Rao,V.A., Parant,J.M.,
Valentin-Vega,Y.A., Terzian,T., Caldwell,L.C., Strong,L.C. et al.
(2004) Gain of function of a p53 hot spot mutation in a mouse model
of Li-Fraumeni syndrome. Cell, 119, 861–872.
20. Deyoung,M.P. and Ellisen,L.W. (2007) p63 and p73 in human cancer:
defining the network. Oncogene, 26, 5169–5183.
21. Schavolt,K.L. and Pietenpol,J.A. (2007) p53 and Np63
differentially bind and regulate target genes involved in cell cycle
arrest, DNA repair and apoptosis. Oncogene, 26, 6125–6132.
22. Rinn,J.L. and Huarte,M. (2011) To repress or not to repress: this is
the guardian’s question. Trends Cell Biol., 21, 344–353.
23. Brady,C.A., Jiang,D., Mello,S.S., Johnson,T.M., Jarvis,L.A.,
Kozak,M.M., Kenzelmann Broz,D., Basak,S., Park,E.J.,
McLaughlin,M.E. et al. (2011) Distinct p53 transcriptional programs
dictate acute DNA-damage responses and tumor suppression. Cell,
145, 571–583.
24. Truong,A.B., Kretz,M., Ridky,T.W., Kimmel,R. and Khavari,P.A.
(2006) p63 regulates proliferation and differentiation of
developmentally mature keratinocytes. Genes Dev., 20, 3185–3197.
25. McDade,S.S., Patel,D. and McCance,D.J. (2011) p63 maintains
keratinocyte proliferative capacity through regulation of Skp2-p130
levels. J. Cell Sci., 124, 1635–1643.
26. McDade,S.S.S., Henry,A.E.A., Pivato,G.P.G., Kozarewa,I.I.,
Mitsopoulos,C.C., Fenwick,K.K., Assiotis,I.I., Hakas,J.J.,
Zvelebil,M.M., Orr,N.N. et al. (2012) Genome-wide analysis of p63
binding sites identifies AP-2 factors as co-regulators of epidermal
differentiation. Nucleic Acids Res., 40, 7190–7206.
27. Shin,H., Liu,T., Manrai,A.K. and Liu,X.S. (2009) CEAS:
cis-regulatory element annotation system. Bioinformatics, 25,
2605–2606.
28. Botcheva,K.K., McCorkle,S.R.S., McCombie,W.R.W., Dunn,J.J.J.
and Anderson,C.W.C. (2011) Distinct p53 genomic binding patterns
in normal and cancer-derived human cells. Cell Cycle, 10, 4237–4249.
29. Smeenk,L., van Heeringen,S.J., Koeppel,M., Gilbert,B.,
Janssen-Megens,E., Stunnenberg,H.G. and Lohrum,M. (2011) Role
of p53 serine 46 in p53 target gene regulation. PLoS One, 6, e17574.
30. Incassati,A., Patel,D. and McCance,D.J. (2006) Induction of
tetraploidy through loss of p53 and upregulation of Plk1 by human
papillomavirus type-16 E6. Oncogene, 25, 2444–2451.
31. Supek,F., Bosˇnjak,M., Sˇkunca,N. and Sˇmuc,T. (2011) REVIGO
summarizes and visualizes long lists of gene ontology terms. PLoS
One, 6, e21800.
32. Huang,D.W., Sherman,B.T. and Lempicki,R.A. (2009) Systematic
and integrative analysis of large gene lists using DAVID
bioinformatics resources. Nat. Protoc., 4, 44–57.
33. Schmidt,D., Wilson,M.D., Spyrou,C., Brown,G.D., Hadfield,J. and
Odom,D.T. (2009) ChIP-seq: using high-throughput sequencing to
discover protein-DNA interactions.Methods, 48, 240–248.
34. Zhang,Y., Liu,T., Meyer,C.A., Eeckhoute,J., Johnson,D.S.,
Bernstein,B.E., Nussbaum,C., Myers,R.M., Brown,M., Li,W. et al.
(2008) Model-based analysis of ChIP-Seq (MACS). Genome Biol, 9,
R137.1–R137.9.
35. ENCODE Project Consortium (2011) A user’s guide to the
encyclopedia of DNA elements (ENCODE). PLoS Biol., 9, e1001046.
36. Edgar,R., Domrachev,M. and Lash,A.E. (2002) Gene Expression
Omnibus: NCBI gene expression and hybridization array data
repository. Nucleic Acids Res., 30, 207–210.
37. Ross-Innes,C.S.C., Stark,R.R., Teschendorff,A.E.A.,
Holmes,K.A.K., Ali,H.R.H., Dunning,M.J.M., Brown,G.D.G.,
Gojis,O.O., Ellis,I.O.I., Green,A.R.A. et al. (2012) Differential
oestrogen receptor binding is associated with clinical outcome in
breast cancer. Nature, 481, 389–393.
38. Robinson,J.T., Thorvaldsdo´ttir,H., Winckler,W., Guttman,M.,
Lander,E.S., Getz,G. and Mesirov,J.P. (2011) Integrative genomics
viewer. Nat. Biotechnol., 29, 24–26.
39. Ji,X., Li,W., Song,J., Wei,L. and Liu,X.S. (2006) CEAS: cis-regulatory
element annotation system. Nucleic Acids Res., 34, W551–W554.
40. Saldanha,A.J. (2004) Java Treeview––extensible visualization of
microarray data. Bioinformatics, 20, 3246–3248.
41. Machanick,P. and Bailey,T.L. (2011) MEME-ChIP: motif analysis of
large DNA datasets. Bioinformatics, 27, 1696–1697.
42. Liu,T., Ortiz,J.A., Taing,L., Meyer,C.A., Lee,B., Zhang,Y., Shin,H.,
Wong,S.S., Ma,J., Lei,Y. et al. (2011) Cistrome: an integrative
platform for transcriptional regulation studies. Genome Biol., 12,
R83.1–R83.10
43. Emig,D., Salomonis,N., Baumbach,J., Lengauer,T., Conklin,B.R. and
Albrecht,M. (2010) AltAnalyze and DomainGraph: analyzing and
visualizing exon expression data. Nucleic Acids Res, 38, W755–W762.
44. Dreszer,T.R., Karolchik,D., Zweig,A.S., Hinrichs,A.S., Raney,B.J.,
Kuhn,R.M., Meyer,L.R., Wong,M., Sloan,C.A., Rosenbloom,K.R.
et al. (2011) The UCSC Genome Browser database: extensions and
updates 2011. Nucleic Acids Res, 40, D918–D923.
45. Goecks,J., Nekrutenko,A., Taylor,J. and Galaxy Team (2010)
Galaxy: a comprehensive approach for supporting accessible,
reproducible, and transparent computational research in the life
sciences. Genome Biol, 11, R86.1–R86.13.
46. Blankenberg,D., Kuster,Von, G., Coraor,N., Ananda,G., Lazarus,R.,
Mangan,M., Nekrutenko,A. and Taylor,J. (2010) Galaxy: a
web-based genome analysis tool for experimentalists. Curr. Protoc.
Mol. Biol., Chapter 19, Unit 19.10.1–19.10.21.
47. Heintzman,N.D., Stuart,R.K., Hon,G., Fu,Y., Ching,C.W.,
Hawkins,R.D., Barrera,L.O., Van Calcar,S., Qu,C., Ching,K.A. et al.
(2007) Distinct and predictive chromatin signatures of transcriptional
promoters and enhancers in the human genome. Nat. Genet., 39,
311–318.
48. Ye,T., Krebs,A.R., Choukrallah,M.A., Keime,C., Plewniak,F.,
Davidson,I. and Tora,L. (2011) seqMINER: an integrated ChIP-seq
data interpretation platform. Nucleic Acids Res., 39, e35–e35.
 at Institute of Cancer Research on July 11, 2016
http://nar.oxfordjournals.org/
D
ow
nloaded from
 
Nucleic Acids Research, 2014, Vol. 42, No. 10 6285
49. Rosenbloom,K.R., Dreszer,T.R., Pheasant,M., Barber,G.P.,
Meyer,L.R., Pohl,A., Raney,B.J., Wang,T., Hinrichs,A.S., Zweig,A.S.
et al. (2010) ENCODE whole-genome data in the UCSC Genome
Browser. Nucleic Acids Res., 38, D620–D625.
50. Agrawal,N., Frederick,M.J., Pickering,C.R., Bettegowda,C.,
Chang,K., Li,R.J., Fakhry,C., Xie,T.-X., Zhang,J., Wang,J. et al.
(2011) Exome sequencing of head and neck squamous cell carcinoma
reveals inactivating mutations in NOTCH1. Science, 333, 1154–1157.
51. Thurlow,J.K., Pen˜a Murillo,C.L., Hunter,K.D., Buffa,F.M.,
Patiar,S., Betts,G., West,C.M.L., Harris,A.L., Parkinson,E.K.,
Harrison,P.R. et al. (2010) Spectral clustering of microarray data
elucidates the roles of microenvironment remodeling and immune
responses in survival of head and neck squamous cell carcinoma. J.
Clin. Oncol., 28, 2881–2888.
52. Pyeon,D., Newton,M.A., Lambert,P.F., den Boon,J.A., Sengupta,S.,
Marsit,C.J., Woodworth,C.D., Connor,J.P., Haugen,T.H., Smith,E.M.
et al. (2007) Fundamental differences in cell cycle deregulation in
human papillomavirus-positive and human papillomavirus-negative
head/neck and cervical cancers. Cancer Res., 67, 4605–4619.
53. Fury,W., Batliwalla,F., Gregersen,P.K. and Li,W. (2006) Overlapping
probabilities of top ranking gene lists, hypergeometric distribution,
and stringency of gene selection criterion. Conf. Proc. IEEE Eng.
Med. Biol. Soc., 1, 5531–5534.
54. Chacko,A.D., McDade,S.S., Chanduloy,S., Church,S.W.,
Kennedy,R., Price,J., Hall,P.A. and Russell,S.E.H. (2012) Expression
of the SEPT9 i4 isoform confers resistance to microtubule-interacting
drugs. Cell Oncol. (Dordr.), 35, 85–93.
55. Kouwenhoven,E.N., van Heeringen,S.J., Tena,J.J., Oti,M.,
Dutilh,B.E., Alonso,M.E., de la Calle-Mustienes,E., Smeenk,L.,
Rinne,T., Parsaulian,L. et al. (2010) Genome-wide profiling of p63
DNA-binding sites identifies an element that regulates gene
expression during limb development in the 7q21 SHFM1 locus. PLoS
Genet., 6, e1001065.
56. Koeppel,M., van Heeringen,S.J., Kramer,D., Smeenk,L.,
Janssen-Megens,E., Hartmann,M., Stunnenberg,H.G. and
Lohrum,M. (2011) Crosstalk between c-Jun and TAp73alpha/beta
contributes to the apoptosis-survival balance. Nucleic Acids Res., 39,
6069–6085.
57. Carroll,J.S., Meyer,C.A., Song,J., Li,W., Geistlinger,T.R.,
Eeckhoute,J., Brodsky,A.S., Keeton,E.K., Fertuck,K.C., Hall,G.F.
et al. (2006) Genome-wide analysis of estrogen receptor binding sites.
Nat. Genet., 38, 1289–1297.
58. Tan,T. and Chu,G. (2002) p53 Binds and activates the xeroderma
pigmentosum DDB2 gene in humans but not mice.Mol. Cell. Biol.,
22, 3247–3254.
59. Tanaka,H., Arakawa,H., Yamaguchi,T., Shiraishi,K., Fukuda,S.,
Matsui,K., Takei,Y. and Nakamura,Y. (2000) A ribonucleotide
reductase gene involved in a p53-dependent cell-cycle checkpoint for
DNA damage. Nature, 404, 42–49.
60. Schlereth,K., Heyl,C., Krampitz,A.-M., Mernberger,M.,
Finkernagel,F., Scharfe,M., Jarek,M., Leich,E., Rosenwald,A. and
Stiewe,T. (2013) Characterization of the p53 cistrome–DNA binding
cooperativity dissects p53’s tumor suppressor functions. PLoS Genet.,
9, e1003726.
61. Timofeev,O., Schlereth,K., Wanzel,M., Braun,A., Nieswandt,B.,
Pagenstecher,A., Rosenwald,A., Elsa¨sser,H.-P. and Stiewe,T. (2013)
p53 DNA binding cooperativity is essential for apoptosis and tumor
suppression in vivo. Cell Rep., 3, 1512–1525.
62. Menendez,D., Nguyen,T.-A., Freudenberg,J.M., Mathew,V.J.,
Anderson,C.W., Jothi,R. and Resnick,M.A. (2013) Diverse stresses
dramatically alter genome-wide p53 binding and transactivation
landscape in human cancer cells. Nucleic Acids Res., 15, 7286–7301.
63. Barlow,C., Brown,K.D., Deng,C.-X., Tagle,D.A. and
Wynshaw-Boris,A. (1997) Atm selectively regulates distinct
p53-dependent cell-cycle checkpoint and apoptotic pathways. Nat.
Genet., 17, 453–456.
64. Huang,Y., Sen,T., Nagpal,J., Upadhyay,S., Trink,B., Ratovitski,E.
and Sidransky,D. (2008) ATM kinase is a master switch for the Delta
Np63 alpha phosphorylation/degradation in human head and neck
squamous cell carcinoma cells upon DNA damage. Cell Cycle, 7,
2846–2855.
65. Kurz,E.U., Douglas,P. and Lees-Miller,S.P. (2004) Doxorubicin
activates ATM-dependent phosphorylation of multiple downstream
targets in part through the generation of reactive oxygen species. J.
Biol. Chem., 279, 53272–53281.
66. Aksoy,O., Chicas,A., Zeng,T., Zhao,Z., McCurrach,M., Wang,X.
and Lowe,S.W. (2012) The atypical E2F family member E2F7 couples
the p53 and RB pathways during cellular senescence. Genes Dev., 26,
1546–1557.
67. Antonini,D., Rossi,B., Han,R., Minichiello,A., Di Palma,T.,
Corrado,M., Banfi,S., Zannini,M., Brissette,J.L. and Missero,C.
(2006) An autoregulatory loop directs the tissue-specific expression of
p63 through a long-range evolutionarily conserved enhancer.Mol.
Cell. Biol., 26, 3308–3318.
68. Li,M.M., He,Y.Y., Dubois,W.W., Wu,X.X., Shi,J.J. and Huang,J.J.
(2012) Distinct regulatory mechanisms and functions for
p53-activated and p53-repressed DNA damage response genes in
embryonic stem cells.Mol. Cell, 46, 30–42.
69. Liu,Y.-Y., Patwardhan,G.A., Bhinge,K., Gupta,V., Gu,X. and
Jazwinski,S.M. (2011) Suppression of glucosylceramide synthase
restores p53-dependent apoptosis in mutant p53 cancer cells. Cancer
Res., 71, 2276–2285.
70. Lin,Y.-L., Sengupta,S., Gurdziel,K., Bell,G.W., Jacks,T., Flores,E.R.
and Ford,J.M. (2009) p63 and p73 transcriptionally regulate genes
involved in DNA repair. PLoS Genet., 5, e1000680–e1000680.
71. Nikulenkov,F.F., Spinnler,C.C., Li,H.H., Tonelli,C.C., Shi,Y.Y.,
Turunen,M.M., Kivioja,T.T., Ignatiev,I.I., Kel,A.A., Taipale,J.J. et al.
(2012) Insights into p53 transcriptional function via genome-wide
chromatin occupancy and gene expression analysis. Cell Death
Differ., 19, 1992–2002.
72. Ramsey,M.R., Wilson,C., Ory,B., Rothenberg,S.M., Faquin,W.,
Mills,A.A. and Ellisen,L.W. (2013) FGFR2 signaling underlies p63
oncogenic function in squamous cell carcinoma. J. Clin. Invest., 123,
3525–3538.
73. Gallant-Behm,C.L., Ramsey,M.R., Bensard,C.L., Nojek,I., Tran,J.,
Liu,M., Ellisen,L.W. and Espinosa,J.M. (2012) Np63 represses
anti-proliferative genes via H2A.Z deposition. Genes Dev., 26,
2325–2336.
74. Su,X., Chakravarti,D. and Flores,E.R. (2012) p63 steps into the
limelight: crucial roles in the suppression of tumorigenesis and
metastasis. Nat. Rev. Cancer, 13, 136–143.
75. Levine,A.J. and Oren,M. (2009) The first 30 years of p53: growing
ever more complex. Nat. Rev. Cancer, 9, 749–758.
76. Gaiddon,C., Lokshin,M., Ahn,J., Zhang,T. and Prives,C. (2001) A
subset of tumor-derived mutant forms of p53 down-regulate p63 and
p73 through a direct interaction with the p53 core domain.Mol. Cell.
Biol., 21, 1874–1887.
 at Institute of Cancer Research on July 11, 2016
http://nar.oxfordjournals.org/
D
ow
nloaded from
 
